CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.0713
1.6%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0974
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

OncoCyte Corp ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.1213
Open* 3.1213
1-Year Change* 327.58%
Day's Range* 3.0713 - 3.1213
52 wk Range 3.24-19.28
Average Volume (10 days) 16.99K
Average Volume (3 months) 444.25K
Market Cap 27.11M
P/E Ratio -100.00K
Shares Outstanding 8.24M
Revenue 1.10M
EPS -2.77
Dividend (Yield %) N/A
Beta 1.59
Next Earnings Date Nov 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 3.1213 -0.0800 -2.50% 3.2013 3.2013 3.1113
Sep 28, 2023 3.1913 0.0500 1.59% 3.1413 3.2213 3.1413
Sep 27, 2023 3.1113 0.0000 0.00% 3.1113 3.1113 3.1113
Sep 26, 2023 3.2513 0.0400 1.25% 3.2113 3.3213 3.2113
Sep 25, 2023 3.1913 -0.0500 -1.54% 3.2413 3.2413 3.1913
Sep 22, 2023 3.2113 0.0000 0.00% 3.2113 3.2113 3.2113
Sep 21, 2023 3.1113 -0.0300 -0.96% 3.1413 3.1913 3.0513
Sep 20, 2023 3.2313 0.0100 0.31% 3.2213 3.3313 3.2213
Sep 19, 2023 3.2913 -0.0800 -2.37% 3.3713 3.3713 3.2913
Sep 18, 2023 3.3313 0.1200 3.74% 3.2113 3.3813 3.1613
Sep 15, 2023 3.1713 -0.0500 -1.55% 3.2213 3.2213 3.1713
Sep 14, 2023 3.2713 0.0200 0.62% 3.2513 3.2913 3.2213
Sep 13, 2023 3.2913 0.0200 0.61% 3.2713 3.3413 3.2713
Sep 12, 2023 3.3413 0.1000 3.09% 3.2413 3.3913 3.2413
Sep 11, 2023 3.2213 -0.0700 -2.13% 3.2913 3.3213 3.2213
Sep 8, 2023 3.2881 0.0300 0.92% 3.2581 3.3681 3.2581
Sep 7, 2023 3.2781 -0.1600 -4.65% 3.4381 3.4381 3.2581
Sep 6, 2023 3.3481 0.0100 0.30% 3.3381 3.3581 3.2881
Sep 5, 2023 3.3581 -0.0800 -2.33% 3.4381 3.4381 3.3281
Sep 1, 2023 3.4381 -0.1300 -3.64% 3.5681 3.6281 3.4381

OncoCyte Corporation Events

Time (UTC) Country Event
Wednesday, November 8, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 OncoCyte Corp Earnings Release
Q3 2023 OncoCyte Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.958 2.198 1.216 0 0
Total Operating Expense 18.955 54.782 30.927 22.392 15.202
Selling/General/Admin. Expenses, Total 21.533 20.392 23.282 15.445 8.688
Research & Development 6.965 4.807 9.378 6.794 6.514
Operating Income -17.997 -52.584 -29.711 -22.392 -15.202
Interest Income (Expense), Net Non-Operating -0.548 -0.25 -1.502 -0.031 -0.643
Net Income Before Taxes -18.612 -52.871 -31.186 -22.426 -15.754
Net Income After Taxes -18.612 -43.61 -29.932 -22.426 -15.754
Net Income Before Extra. Items -18.612 -43.61 -29.932 -22.426 -15.754
Net Income -72.902 -64.097 -29.932 -22.426 -15.754
Income Available to Common Excl. Extra. Items -19.132 -43.61 -29.932 -22.426 -15.754
Income Available to Common Incl. Extra. Items -73.422 -64.097 -29.932 -22.426 -15.754
Diluted Net Income -73.422 -64.097 -29.932 -22.426 -15.754
Diluted Weighted Average Shares 5.54 4.446 3.2739 2.5648 1.8925
Diluted EPS Excluding Extraordinary Items -3.45343 -9.80882 -9.14261 -8.74376 -8.32444
Diluted Normalized EPS 0.19007 -9.61715 -9.05883 -8.68411 -8.32444
Other, Net -0.067 -0.037 0.027 -0.003 0.091
Total Extraordinary Items -54.29 -20.487
Unusual Expense (Income) 20.185 1.311 0.422 0.153
Revenue 0.958 2.198 1.216
Cost of Revenue, Total 0.976 0.778 1.855
Gross Profit -0.018 1.42 -0.639
Other Operating Expenses, Total -31.019 27.266 -4.01
Depreciation / Amortization 0.315 0.228
Total Adjustments to Net Income -0.52 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.463 0.297 0.958 1.017 0.237
Revenue 0.463 0.297 0.958 1.017 0.237
Cost of Revenue, Total 0.191 0.287 0.976 2.191 0.206
Gross Profit 0.272 0.01 -0.018 -1.174 0.031
Total Operating Expense 8.757 -5.553 18.955 10.238 1.863
Selling/General/Admin. Expenses, Total 3.855 4.107 21.533 9.21 5.448
Research & Development 1.924 1.764 6.965 4.125 2.363
Other Operating Expenses, Total 1.795 -18.307 -31.019 -6.142 -6.359
Operating Income -8.294 5.85 -17.997 -9.221 -1.626
Interest Income (Expense), Net Non-Operating -0.023 0.111 -0.548 -0.174 -0.016
Other, Net -0.016 -0.002 -0.067 0.062 0.278
Net Income Before Taxes -8.333 5.959 -18.612 -9.333 -1.364
Net Income After Taxes -8.333 5.959 -18.612 -9.333 -1.364
Net Income Before Extra. Items -8.333 5.959 -18.612 -9.333 -1.364
Net Income -8.333 3.033 -72.902 -9.333 -8.3
Income Available to Common Excl. Extra. Items -8.644 5.729 -19.132 -9.555 -1.436
Income Available to Common Incl. Extra. Items -8.644 2.803 -73.422 -9.555 -8.372
Diluted Net Income -8.644 2.803 -73.422 -9.555 -8.372
Diluted Weighted Average Shares 8.09 7.56 5.54 5.9305 5.652
Diluted EPS Excluding Extraordinary Items -1.06848 0.7578 -3.45343 -1.61116 -0.25407
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.98937 1.58228 0.19007 -1.51707 -0.23213
Unusual Expense (Income) 0.64 6.233 20.185 0.558 0.124
Depreciation / Amortization 0.352 0.363 0.315 0.296 0.081
Total Extraordinary Items 0 -2.926 -54.29 -6.936
Total Adjustments to Net Income -0.311 -0.23 -0.52 -0.222 -0.072
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 25.536 39.143 9.226 22.956 8.642
Cash and Short Term Investments 20.426 36.509 7.818 22.451 8.462
Cash & Equivalents 19.993 35.605 7.143 22.072 8.034
Short Term Investments 0.433 0.904 0.675 0.379 0.428
Prepaid Expenses 0.977 0.693 1.205 0.505 0.18
Other Current Assets, Total 2.121
Total Assets 100.091 159.563 55.419 39.859 9.518
Property/Plant/Equipment, Total - Net 10.851 8.527 6.524 3.728 0.614
Property/Plant/Equipment, Total - Gross 15.047 11.242 7.964 4.071 1.562
Accumulated Depreciation, Total -4.196 -2.715 -1.44 -0.343 -0.948
Intangibles, Net 61.633 91.245 15.009 0
Other Long Term Assets, Total 2.071 1.964 2.056 2.211 0.262
Total Current Liabilities 12.106 14.12 8.996 4.44 5.561
Accounts Payable 1.253 2.447 0.432 0.469 0.166
Accrued Expenses 8.731 10.256 5.423 2.769 2.109
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.117 1.417 2.541 1.196 1.185
Other Current Liabilities, Total 2.005 0.6 0.006 2.101
Total Liabilities 60.497 94.346 21.936 9.021 6.095
Total Long Term Debt 0 0.117 1.729 1.963 0.534
Capital Lease Obligations 0 0.117 0.221 0.058 0.187
Total Equity 39.594 65.217 33.483 30.838 3.423
Preferred Stock - Non Redeemable, Net 5.302 0 0
Common Stock 294.929 252.954 157.16 124.583 74.742
Retained Earnings (Accumulated Deficit) -260.676 -187.774 -123.677 -93.745 -71.319
Other Equity, Total 0.039 0.037 0
Total Liabilities & Shareholders’ Equity 100.091 159.563 55.419 39.859 9.518
Total Common Shares Outstanding 118.644 92.232 69.117 57.032 40.664
Long Term Debt 0 1.508 1.905 0.347
Long Term Investments 0 13.417 10.964
Other Liabilities, Total 48.391 80.109 11.211 2.618
Total Receivables, Net 2.012 1.637 0.203
Accounts Receivable - Trade, Net 2.012 1.437 0.203
Goodwill, Net 0 18.684 9.187
Total Inventory 0.304
Total Preferred Shares Outstanding 0.00001
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 15.648 25.536 36.636 49.368 24.623
Cash and Short Term Investments 12.356 20.426 32.472 45.415 20.986
Cash & Equivalents 11.803 19.993 32.053 44.836 20.412
Short Term Investments 0.553 0.433 0.419 0.579 0.574
Total Receivables, Net 1.901 2.012 1.99 1.802 2.122
Accounts Receivable - Trade, Net 1.901 2.012 1.99 1.802 2.122
Prepaid Expenses 0.97 0.977 2.174 2.151 1.515
Total Assets 82.8 100.091 157.344 171.051 146.273
Property/Plant/Equipment, Total - Net 8.424 10.851 11.593 11.576 10.651
Property/Plant/Equipment, Total - Gross 13.196 15.047 15.73 15.197 13.769
Accumulated Depreciation, Total -4.772 -4.196 -4.137 -3.621 -3.117
Goodwill, Net 0 18.684 18.684 18.684
Intangibles, Net 56.661 61.633 88.365 89.341 90.317
Long Term Investments
Other Long Term Assets, Total 2.067 2.071 2.066 2.082 1.998
Total Current Liabilities 9.43 12.106 12.952 14.154 13.955
Accounts Payable 1.395 1.253 1.826 2.465 2.584
Accrued Expenses 7.71 8.731 11.013 11.005 10.319
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.089 0.117 0.113 0.684 1.052
Other Current Liabilities, Total 0.236 2.005
Total Liabilities 39.335 60.497 75.411 82.954 89.306
Total Long Term Debt 0 0 0.031 0.06 0.089
Long Term Debt
Capital Lease Obligations 0 0 0.031 0.06 0.089
Other Liabilities, Total 29.905 48.391 62.428 68.74 75.262
Total Equity 43.465 39.594 81.933 88.097 56.967
Common Stock 295.533 294.929 292.536 289.649 254.994
Retained Earnings (Accumulated Deficit) -257.643 -260.676 -215.698 -206.437 -198.065
Total Liabilities & Shareholders’ Equity 82.8 100.091 157.344 171.051 146.273
Total Common Shares Outstanding 119.279 118.644 118.619 118.609 92.247
Other Equity, Total 0.043 0.039 0.019 0.031 0.038
Preferred Stock - Non Redeemable, Net 5.532 5.302 5.076 4.854
Other Current Assets, Total 0.421 2.121
Total Preferred Shares Outstanding 0.00001 0.00001
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -72.902 -64.097 -29.932 -22.426 -15.754
Cash From Operating Activities -45.568 -35.941 -25.98 -19.715 -11.649
Cash From Operating Activities 1.528 0.844 0.313 0.344 0.438
Amortization 3.692 3.361 0.081 0 0.121
Non-Cash Items 24.056 35.415 4.413 3.922 2.553
Changes in Working Capital -1.942 -2.203 0.399 -1.555 0.993
Cash From Investing Activities -4.34 -13.961 -11.748 -12.415 -0.031
Capital Expenditures -4.34 -2.247 -1.227 -0.918 -0.031
Other Investing Cash Flow Items, Total 0 -11.714 -10.521 -11.497 0
Cash From Financing Activities 35.806 78.364 22.799 47.868 12.114
Financing Cash Flow Items -0.483 -3.065 -0.132 -3.288 -0.355
Issuance (Retirement) of Stock, Net 37.718 82.963 22.236 49.793 13.65
Issuance (Retirement) of Debt, Net -1.429 -1.534 0.695 1.363 -1.181
Net Change in Cash -14.102 28.462 -14.929 15.738 0.434
Cash Interest Paid 0.024 0.114 0.209 0.171 0.142
Deferred Taxes 0 -9.261 -1.254
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 3.033 -72.902 -27.924 -18.591 -10.291
Cash From Operating Activities -9.672 -45.568 -35.92 -24.568 -13.277
Cash From Operating Activities 0.45 1.528 1.062 0.671 0.287
Amortization 0.022 3.692 2.88 1.904 0.928
Deferred Taxes 0 0 0
Non-Cash Items -11.212 24.056 -9.589 -6.742 -2.309
Cash Interest Paid 0 0.024 0.024 0.021 0.013
Changes in Working Capital -1.965 -1.942 -2.349 -1.81 -1.892
Cash From Investing Activities 0 -4.34 -3.538 -2.679 -1.561
Capital Expenditures 0 -4.34 -3.538 -2.679 -1.561
Other Investing Cash Flow Items, Total 0 0 0 0
Cash From Financing Activities -0.028 35.806 35.906 36.478 -0.355
Financing Cash Flow Items 0 -0.483 -0.483 -0.483 -0.001
Issuance (Retirement) of Stock, Net 0 37.718 37.718 37.718 0.031
Issuance (Retirement) of Debt, Net -0.028 -1.429 -1.329 -0.757 -0.385
Net Change in Cash -9.7 -14.102 -3.552 9.231 -15.193

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

OncoCyte Corporation Company profile

About OncoCyte Corp

Oncocyte Corporation is a molecular diagnostics company. The Company is engaged in developing and commercializing laboratory-developed tests (LDTs) to serve unmet medical needs across the cancer care continuum. The LTDs provide actionable information to physicians and patients to optimize treatment decisions, including the selection of immunotherapy. The Company focuses on the development of a non-invasive confirmatory blood test for lung cancer called DetermaDx. The DetermaDx is the test to predict a post-surgery patient’s risk of cancer recurrence and their response to chemotherapy in early-stage lung cancer. Its development pipeline includes TheraSure CNI Monitor, which is a blood-based test for immunotherapy monitoring, and TheraSure Transplant Monitor, a solid organ transplantation monitoring test. Its other DetermaIO, DetermaCNI, DetermaMx, Keytruda, Opdivo, Tecentriq and Imfinzi.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, OncoCyte Corp revenues increased from $1.2M to $7.7M. Net loss increased from $29.9M to $64.1M. Revenues reflect DetermaRx segment increase from $547K to $2.5M, Pharma Services segment increase from $669K to $1.5M, United States segment increase from $742K to $3.5M. Higher net loss reflects Fair Value Adjustments on Other Assets increase from $4M (income) to $27.3M (expense).

Industry: Bio Therapeutic Drugs

15 Cushing
IRVINE
CALIFORNIA 92618
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

US100

14,782.20 Price
+0.490% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

28,354.30 Price
+4.350% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Gold

1,830.44 Price
-0.940% 1D Chg, %
Long position overnight fee -0.0197%
Short position overnight fee 0.0115%
Overnight fee time 21:00 (UTC)
Spread 0.30

Oil - Crude

88.41 Price
-1.500% 1D Chg, %
Long position overnight fee 0.0659%
Short position overnight fee -0.0878%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading